Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia

Phillip S. Gould, Mei Gu, Jianqin Liao, Shakil Ahmad, Melissa J. Cudmore, Asif Ahmed, Manu Vatish

Research output: Contribution to journalArticle

Abstract

Preeclampsia is a hypertensive disorder of pregnancy caused by abnormal placental function, partly because of chronic hypoxia at the utero-placental junction. The increase in levels of soluble vascular endothelial growth factor receptor 1, an antiangiogenic agent known to inhibit placental vascularization, is an important cellular factor implicated in the onset of preeclampsia. We investigated the ligand urotensin II (U-II), a potent endogenous vasoconstrictor and proangiogenic agent, for which levels have been reported to increase in patients with preeclampsia. We hypothesized that an increased sensitivity to U-II in preeclampsia might be achieved by upregulation of placental U-II receptors. We further investigated the role of U-II receptor stimulation on soluble vascular endothelial growth factor receptor 1 release in placental explants from diseased and normal patients. Immunohistochemistry, real-time PCR, and Western blotting analysis revealed that U-II receptor expression was significantly upregulated in preeclampsia placentas compared with controls (P<0.01). Cellular models of syncytiotrophoblast and vascular endothelial cells subjected to hypoxic conditions revealed an increase in U-II receptor levels in the syncytiotrophoblast model. This induction is regulated by the transcriptional activator hypoxia-inducible factor 1a. U-II treatment is associated with increased secretion of soluble vascular endothelial growth factor receptor 1 only in preeclamptic placental explants under hypoxia but not in control conditions. Interestingly, normal placental explants did not respond to U-II stimulation.
LanguageEnglish
Pages172-178
Number of pages7
JournalHypertension
Volume56
Issue number1
Early online date17 May 2010
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Vascular Endothelial Growth Factor Receptor-1
Pre-Eclampsia
Up-Regulation
Trophoblasts
Placenta Diseases
Angiogenesis Inhibitors
In Vitro Techniques
urotensin II
Hypoxia
Vasoconstrictor Agents
Placenta
Real-Time Polymerase Chain Reaction
Endothelial Cells
Western Blotting
Immunohistochemistry
Ligands
Pregnancy

Keywords

  • urotensin II
  • preeclampsia
  • placenta
  • sVEGFR-1
  • HIF-1α

Cite this

@article{2965b3984bf14916a5b0e8f4a34204a6,
title = "Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia",
abstract = "Preeclampsia is a hypertensive disorder of pregnancy caused by abnormal placental function, partly because of chronic hypoxia at the utero-placental junction. The increase in levels of soluble vascular endothelial growth factor receptor 1, an antiangiogenic agent known to inhibit placental vascularization, is an important cellular factor implicated in the onset of preeclampsia. We investigated the ligand urotensin II (U-II), a potent endogenous vasoconstrictor and proangiogenic agent, for which levels have been reported to increase in patients with preeclampsia. We hypothesized that an increased sensitivity to U-II in preeclampsia might be achieved by upregulation of placental U-II receptors. We further investigated the role of U-II receptor stimulation on soluble vascular endothelial growth factor receptor 1 release in placental explants from diseased and normal patients. Immunohistochemistry, real-time PCR, and Western blotting analysis revealed that U-II receptor expression was significantly upregulated in preeclampsia placentas compared with controls (P<0.01). Cellular models of syncytiotrophoblast and vascular endothelial cells subjected to hypoxic conditions revealed an increase in U-II receptor levels in the syncytiotrophoblast model. This induction is regulated by the transcriptional activator hypoxia-inducible factor 1a. U-II treatment is associated with increased secretion of soluble vascular endothelial growth factor receptor 1 only in preeclamptic placental explants under hypoxia but not in control conditions. Interestingly, normal placental explants did not respond to U-II stimulation.",
keywords = "urotensin II, preeclampsia, placenta, sVEGFR-1, HIF-1α",
author = "Gould, {Phillip S.} and Mei Gu and Jianqin Liao and Shakil Ahmad and Cudmore, {Melissa J.} and Asif Ahmed and Manu Vatish",
year = "2010",
month = "7",
doi = "10.1161/HYPERTENSIONAHA.110.152074",
language = "English",
volume = "56",
pages = "172--178",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia. / Gould, Phillip S.; Gu, Mei; Liao, Jianqin; Ahmad, Shakil; Cudmore, Melissa J.; Ahmed, Asif; Vatish, Manu.

In: Hypertension, Vol. 56, No. 1, 07.2010, p. 172-178.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia

AU - Gould, Phillip S.

AU - Gu, Mei

AU - Liao, Jianqin

AU - Ahmad, Shakil

AU - Cudmore, Melissa J.

AU - Ahmed, Asif

AU - Vatish, Manu

PY - 2010/7

Y1 - 2010/7

N2 - Preeclampsia is a hypertensive disorder of pregnancy caused by abnormal placental function, partly because of chronic hypoxia at the utero-placental junction. The increase in levels of soluble vascular endothelial growth factor receptor 1, an antiangiogenic agent known to inhibit placental vascularization, is an important cellular factor implicated in the onset of preeclampsia. We investigated the ligand urotensin II (U-II), a potent endogenous vasoconstrictor and proangiogenic agent, for which levels have been reported to increase in patients with preeclampsia. We hypothesized that an increased sensitivity to U-II in preeclampsia might be achieved by upregulation of placental U-II receptors. We further investigated the role of U-II receptor stimulation on soluble vascular endothelial growth factor receptor 1 release in placental explants from diseased and normal patients. Immunohistochemistry, real-time PCR, and Western blotting analysis revealed that U-II receptor expression was significantly upregulated in preeclampsia placentas compared with controls (P<0.01). Cellular models of syncytiotrophoblast and vascular endothelial cells subjected to hypoxic conditions revealed an increase in U-II receptor levels in the syncytiotrophoblast model. This induction is regulated by the transcriptional activator hypoxia-inducible factor 1a. U-II treatment is associated with increased secretion of soluble vascular endothelial growth factor receptor 1 only in preeclamptic placental explants under hypoxia but not in control conditions. Interestingly, normal placental explants did not respond to U-II stimulation.

AB - Preeclampsia is a hypertensive disorder of pregnancy caused by abnormal placental function, partly because of chronic hypoxia at the utero-placental junction. The increase in levels of soluble vascular endothelial growth factor receptor 1, an antiangiogenic agent known to inhibit placental vascularization, is an important cellular factor implicated in the onset of preeclampsia. We investigated the ligand urotensin II (U-II), a potent endogenous vasoconstrictor and proangiogenic agent, for which levels have been reported to increase in patients with preeclampsia. We hypothesized that an increased sensitivity to U-II in preeclampsia might be achieved by upregulation of placental U-II receptors. We further investigated the role of U-II receptor stimulation on soluble vascular endothelial growth factor receptor 1 release in placental explants from diseased and normal patients. Immunohistochemistry, real-time PCR, and Western blotting analysis revealed that U-II receptor expression was significantly upregulated in preeclampsia placentas compared with controls (P<0.01). Cellular models of syncytiotrophoblast and vascular endothelial cells subjected to hypoxic conditions revealed an increase in U-II receptor levels in the syncytiotrophoblast model. This induction is regulated by the transcriptional activator hypoxia-inducible factor 1a. U-II treatment is associated with increased secretion of soluble vascular endothelial growth factor receptor 1 only in preeclamptic placental explants under hypoxia but not in control conditions. Interestingly, normal placental explants did not respond to U-II stimulation.

KW - urotensin II

KW - preeclampsia

KW - placenta

KW - sVEGFR-1

KW - HIF-1α

UR - http://www.scopus.com/inward/record.url?scp=77953811161&partnerID=8YFLogxK

UR - http://hyper.ahajournals.org/content/56/1/172

U2 - 10.1161/HYPERTENSIONAHA.110.152074

DO - 10.1161/HYPERTENSIONAHA.110.152074

M3 - Article

VL - 56

SP - 172

EP - 178

JO - Hypertension

T2 - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -